-
MFN Monitor: Europe’s Drug Launch Model Is Becoming a U.S. Pricing Risk
Written by
Traditional Global Launch Strategies Are Now Under Pressure For decades, the commercial path for innovative therapeutics followed a relatively predictable pathway. Secure FDA-approval, establish strategic pricing and a robust commercial footprint in US, and expand into Europe shortly thereafter. That framework has now come under attack due to the uncertainty related to the pricing policy debate between biopharma and the current US administration. The growing political and regulatory scrutiny surrounding Most Favored Nation (MFN) drug…
-
Convergence of US FDA & Drug Pricing
Written by
The FDA, under new leadership, is taking an unprecedented role in drug pricing by linking approval incentives—like Priority Vouchers—to economic impact and Most Favored Nation (MFN) pricing. This blurs the traditional separation between regulatory review and payer negotiation, pressuring prices from day one. These shifts could reshape biopharma valuations, launch strategies, and access dynamics. Companies must closely track policy changes and strengthen development plans that demonstrate meaningful clinical and economic value.
